Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 10 680 / https://doi.org/10.3332/ecancer.2016.680

Clinical Study

Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent

Propranolol (PRO) is a well-known and widely used non-selective beta-adrenergic receptor antagonist (beta-blocker), with a range of actions which are of interest in an oncological context. PRO displays effects on cellular proliferation and invasion, on the immune system, on the angiogenic cascade, and on tumour cell sensitivity to existing treatments. Both pre-clinical and clinical evidence of these effects, in multiple cancer types, is assessed and summarised and relevant mechanisms of action outlined. In particular there is evidence that PRO is effective at multiple points in the metastatic cascade, particularly in the context of the post-surgical wound response. Based on this evidence the case is made for further clinical investigation of the anticancer effects of PRO, particularly in combination with other agents. A number of trials are on-going, in different treatment settings for various cancers.

Keywords: Propranolol, beta-blockers, drug repurposing, ReDO project

Loading Article Metrics ... Please wait

Author interviews

Pan Pantziarka and Lydie Meheus

Anticancer Fund, Belgium

Related videos

Related articles

Case Report: Use of PEG-asparaginase in a case of Hepatosplenic γδ T-cell lymphoma with long-term remission after stem cell transplantation

Abstract | Full Article | PDF Published: 20 Sep 2018 / https://doi.org/10.3332/ecancer.2018.872

Conference Report: Highlights from the 2018 WIN Symposium, 25–26 June 2018, Paris: designing the future of precision oncology

Abstract | Full Article | PDF Published: 12 Sep 2018 / https://doi.org/10.3332/ecancer.2018.871

Conference Report: Inspiration, innovation and integration: highlights from the third ICPCN conference on children’s palliative care, 30th May-2nd June 2018, Durban, South Africa

Abstract | Full Article | PDF Published: 11 Sep 2018 / https://doi.org/10.3332/ecancer.2018.870

Special Issue: Pre-, pro- and synbiotics in cancer prevention and treatment—a review of basic and clinical research

Abstract | Full Article | PDF Published: 05 Sep 2018 / https://doi.org/10.3332/ecancer.2018.869

Special Issue: Gut microbiota, chemotherapy and the host: the influence of the gut microbiota on cancer treatment

Abstract | Full Article | PDF Published: 05 Sep 2018 / https://doi.org/10.3332/ecancer.2018.868



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation